Pharmaceutical Market Europe • February 2025 • 3

COMMENT

Inclusivity, collaboration and targeted care

In our cover story this month, Danny Buckland looks at inclusivity, collaboration and targeted care, and why the challenge of achieving inclusivity for ethnic minorities and women in clinical trials is such a Herculean one.

As Danny says: “The value of inclusivity in health could be immeasurable in tackling disparities that manifest in reduced access to anything from screening and diagnostics to the latest therapies and care, and varying levels of life expectancy influenced by geography income, education, ethnicity and employment status.

“The challenge is huge: ethnic minorities and women are vastly under-represented in clinical trials despite healthcare provision and research showing a clear link between certain patient populations and lower health outcomes.

“Innovation and effort is being channelled into righting this wrong through deeper engagement with patient groups, reformulation of regulation and pharmaceutical companies committing to increasing their reach.” Find out more on page 26.

Also in this issue, an article on pharmacovigilance looks at why local knowledge is so key to global outcomes. As the authors say: “The challenge for companies is to ensure their local affiliates meet local pharmacovigilance (PV) obligations while staying aligned with global PV requirements.

Often, however, companies lack PV expertise at the local level and struggle to achieve a coordinated approach to global PV operations, which results in inefficiencies, delays or non-compliance.” Find out more on page 16.

Looking at the EU vs US perspectives on key clinical trial trends, the article on page 20 highlights the distinct priorities and hurdles faced by sponsors, CROs and sites around the world. As Tanya Kogan says: “One of the most challenging aspects of conducting clinical research is its global nature, as there are significant variances in regional requirements and obstacles. Regulatory, cultural and logistical factors all impact trial design, start-up and execution.”

Our next issue, in March 2025, will look at optimising omnichannel engagement with healthcare professionals. If you would like to make your voice heard on this topic, please get in touch at sales@pmlive.com

I hope you enjoy this issue!

Image

Iona Everson
Group Managing Editor

Keep up to date with the latest developments in the UK and global healthcare marketplace – sign up to daily or weekly news alerts and fortnightly or monthly bulletins on specific topics at  www.pmlive.com/register

Image

THE TEAM
Editorial:
Group Managing Editor
Iona Everson

Deputy Editor
Emily Kimber


Studio:
Executive Director
Karl Equi

Sales:
Business Director
Tara Lovegrove

EDITORIAL ADVISORY BOARD
Philip Atkinson
Founder of Hive-Logic, Lifescience Transformation

Uday Bose
Corporate vice president, head of global marketing oncology, Boehringer Ingelheim

Dr Luc Hermans
VP commercial planning and operations Europe, Asia, Middle East, Gilead Sciences

Stefan Janssens
President EMEA, Cegedim Dendrite

John Morris
Partner, KPMG

Paul Pay
Chief business development officer, Norgine

Mark Rothera
Chief executive officer, Orchard Therapeutics

Ian Talmage
Senior vice president, global marketing, general medicine, Bayer Pharmaceuticals

PUBLISHED BY
PMGroup Worldwide Ltd
44 Maiden Lane
Covent Garden
London
WC2E 7LN


CONTACT US
General enquiries: info@pmlive.com
Editorial: editor@pmlive.com
Advertising: sales@pmlive.com
Subscriptions: subscriptions@pmlive.com

Views expressed by the contributors do not necessarily represent those of the publisher, editor or staff.

© 2025 PMGroup
All rights reserved. No part of this publication may be copied, reproduced, transmitted, photocopied, recorded or stored on any retrieval system without the prior written consent of the publishers.

The magazine is also available at the following subscription rates: £120 UK, £180 Europe, £210 RoW

Image
0